{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:44:36Z","timestamp":1773672276323,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson and Johnson Innovative Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00337-8","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:54:08Z","timestamp":1766040848000},"page":"301-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns and Burden of Chronic Thromboembolic Pulmonary Hypertension Patients across Consultation Settings in the USA"],"prefix":"10.1007","volume":"12","author":[{"given":"Belinda","family":"Rivera-Lebron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly J.","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Gomez","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josanna","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0121-2016","author":"H Gall","year":"2017","unstructured":"Gall H, Hoeper MM, Richter MJ, et al. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev. 2017. https:\/\/doi.org\/10.1183\/16000617.0121-2016.","journal-title":"Eur Respir Rev"},{"key":"337_CR2","doi-asserted-by":"publisher","first-page":"1439411","DOI":"10.3389\/fcvm.2024.1439411","volume":"11","author":"B Simeone","year":"2024","unstructured":"Simeone B, Maggio E, Schirone L, et al. Chronic thromboembolic pulmonary hypertension: the therapeutic assessment. Front Cardiovasc Med. 2024;11:1439411.","journal-title":"Front Cardiovasc Med"},{"issue":"suppl 64","key":"337_CR3","first-page":"1547","volume":"56","author":"C Gerges","year":"2020","unstructured":"Gerges C, Friewald R, Shafran I, et al. BPA for CTEPH: the Viennese experience. Eur Respir J. 2020;56(suppl 64):1547.","journal-title":"Eur Respir J"},{"issue":"143","key":"337_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0119-2016","volume":"26","author":"I Lang","year":"2017","unstructured":"Lang I, Meyer BC, Ogo T, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160119.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"337_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.14797\/mdcj-12-4-205","volume":"12","author":"TM Fernandes","year":"2016","unstructured":"Fernandes TM, Poch DS, Auger WR. Treatment of chronic thromboembolic pulmonary hypertension: the role of medical therapy and balloon pulmonary angioplasty. Methodist Debakey Cardiovasc J. 2016;12(4):205\u201312.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"337_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.chest.2023.03.029","volume":"164","author":"J Yang","year":"2023","unstructured":"Yang J, Madani MM, Mahmud E, Kim NH. Evaluation and management of chronic thromboembolic pulmonary hypertension. Chest. 2023;164(2):490\u2013502.","journal-title":"Chest"},{"issue":"3","key":"337_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.hfc.2018.02.009","volume":"14","author":"CJ Mullin","year":"2018","unstructured":"Mullin CJ, Klinger JR. Chronic thromboembolic pulmonary hypertension. Heart Fail Clin. 2018;14(3):339\u201351.","journal-title":"Heart Fail Clin"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vhri.2020.06.005","volume":"24","author":"H Kinoshita","year":"2021","unstructured":"Kinoshita H, Aoki T, Motoki H, et al. Patient journey and disease-related burden in Japanese patients with chronic thromboembolic pulmonary hypertension: a mixed methods study. Value Health Reg Issues. 2021;24:17\u201323.","journal-title":"Value Health Reg Issues"},{"issue":"15","key":"337_CR9","first-page":"4983","volume":"25","author":"K Sarzy\u0144ska","year":"2021","unstructured":"Sarzy\u0144ska K, \u015awi\u0105toniowska-Lonc N, Dudek K, et al. Quality of life of patients with pulmonary arterial hypertension: a meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(15):4983\u201398.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"337_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41687-021-00327-9","volume":"5","author":"B Currie","year":"2021","unstructured":"Currie B, Davies E, Beaudet A, Stassek L, Kleinman L. Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT\u2122) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study. J Patient Rep Outcomes. 2021;5(1):51.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"337_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-080068","volume":"14","author":"DG Kiely","year":"2024","unstructured":"Kiely DG, Hamilton N, Wood S, et al. Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open. 2024;14(1):e080068.","journal-title":"BMJ Open"},{"issue":"2","key":"337_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12406","volume":"14","author":"N Skoro-Sajer","year":"2024","unstructured":"Skoro-Sajer N, Sheares K, Forfia P, et al. Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH):\u00a0a global cross-sectional scientific survey (CLARITY). Pulm Circ. 2024;14(2):e12406.","journal-title":"Pulm Circ"},{"issue":"1","key":"337_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1186\/s12890-024-03442-7","volume":"24","author":"R Kendrew","year":"2024","unstructured":"Kendrew R, Ajraoui S, Beaudet A, et al. Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study. BMC Pulm Med. 2024;24(1):608.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"337_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12330","volume":"14","author":"G Kope\u0107","year":"2024","unstructured":"Kope\u0107 G, Forfia P, Abe K, et al. Recognition, diagnosis, and operability assessment of chronic thromboembolic pulmonary hypertension (CTEPH): a\u00a0global cross-sectional scientific survey (CLARITY). Pulm Circ. 2024;14(1):e12330.","journal-title":"Pulm Circ"},{"issue":"10","key":"337_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/imj.16470","volume":"54","author":"H Barnes","year":"2024","unstructured":"Barnes H, Niewodowski D, Doi A, et al. Current surgical management of chronic thromboembolic pulmonary disease. Intern Med J. 2024;54(10):1616\u201325.","journal-title":"Intern Med J"},{"issue":"38","key":"337_CR16","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"337_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01915-2018","author":"NH Kim","year":"2019","unstructured":"Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.01915-2018.","journal-title":"Eur Respir J"},{"issue":"3","key":"337_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12432","volume":"14","author":"J Issard","year":"2024","unstructured":"Issard J, Fadel E, Dolidon S, et al. Balloon pulmonary angioplasty for proximal chronic thromboembolic pulmonary hypertension in patients ineligible for pulmonary endarterectomy. Pulm Circ. 2024;14(3):e12432.","journal-title":"Pulm Circ"},{"key":"337_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01294-2024","author":"NH Kim","year":"2024","unstructured":"Kim NH, D\u2019Armini AM, Delcroix M, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.01294-2024.","journal-title":"Eur Respir J"},{"issue":"2","key":"337_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.21037\/acs-2021-pte-12","volume":"11","author":"T Verbelen","year":"2022","unstructured":"Verbelen T, Godinas L, Maleux G, et al. Chronic thromboembolic pulmonary hypertension: diagnosis, operability assessment and patient selection for pulmonary endarterectomy. Ann Cardiothorac Surg. 2022;11(2):82\u201397.","journal-title":"Ann Cardiothorac Surg"},{"issue":"null","key":"337_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/DDDT.S117277","volume":"11","author":"T-Y Lian","year":"2017","unstructured":"Lian T-Y, Jiang X, Jing Z-C. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Design Dev Therapy. 2017;11(null):1195\u2013207.","journal-title":"Drug Design Dev Therapy"},{"issue":"5","key":"337_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1183\/09031936.00087114","volume":"45","author":"G Simonneau","year":"2014","unstructured":"Simonneau G, D\u2019Armini AM, Ghofrani H-A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2014;45(5):1293\u2013302.","journal-title":"Eur Respir J"},{"issue":"22","key":"337_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026211","volume":"100","author":"M Ying","year":"2021","unstructured":"Ying M, Song J, Gu S, Zhao R, Li M. Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: a meta-analysis. Medicine (Baltimore). 2021;100(22):e26211.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"337_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","volume":"10","author":"X Ja\u00efs","year":"2022","unstructured":"Ja\u00efs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961\u201371.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"337_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","volume":"10","author":"T Kawakami","year":"2022","unstructured":"Kawakami T, Matsubara H, Shinke T, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respir Med. 2022;10(10):949\u201360.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"337_CR26","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014A means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"337_CR27","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"337_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"337_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"337_CR30","doi-asserted-by":"crossref","unstructured":"EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"5","key":"337_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"337_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.chest.2018.04.027","volume":"154","author":"KM Chin","year":"2018","unstructured":"Chin KM, Gomberg-Maitland M, Channick RN, et al. Psychometric validation of the pulmonary arterial hypertension-symptoms and impact (PAH-SYMPACT) questionnaire: results of the SYMPHONY Trial. Chest. 2018;154(4):848\u201361.","journal-title":"Chest"},{"issue":"1","key":"337_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12931-016-0388-6","volume":"17","author":"D McCollister","year":"2016","unstructured":"McCollister D, Shaffer S, Badesch DB, et al. Development of the pulmonary arterial hypertension-symptoms and impact (PAH-SYMPACT\u00ae) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016;17(1):72.","journal-title":"Respir Res"},{"key":"337_CR34","first-page":"114","volume-title":"Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis","author":"Criteria Committee, New York Heart Association, Inc.","year":"1964","unstructured":"Criteria Committee, New York Heart Association, Inc. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis. 6th edition. Boston: Little, Brown and Co.; 1964. p. 114.","edition":"6th edition"},{"key":"337_CR35","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of conduct https:\/\/www.ephmra.org\/media\/4857\/ephmra-2020-code-of-conduct-final.pdf. Published 2020. Updated September 2020. Accessed 21 Mar 2022."},{"key":"337_CR36","unstructured":"US Department of Health and Human Services. Summary of the HIPAA privacy rule. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Published 2003. Accessed 21 Mar 2023."},{"key":"337_CR37","unstructured":"Health Information Technology (HITECH). Health Information Technology Act. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Published 2009. Accessed 21 Mar 2023."},{"key":"337_CR38","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"issue":"24","key":"337_CR39","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1161\/CIRCULATIONAHA.116.024201","volume":"134","author":"T Inami","year":"2016","unstructured":"Inami T, Kataoka M, Yanagisawa R, et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Circulation. 2016;134(24):2030\u20132.","journal-title":"Circulation"},{"key":"337_CR40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02095-2018","author":"P Brenot","year":"2019","unstructured":"Brenot P, Ja\u00efs X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.02095-2018.","journal-title":"Eur Respir J"},{"issue":"3","key":"337_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s11239-020-02056-0","volume":"50","author":"M Wang","year":"2020","unstructured":"Wang M, Holbrook A, Lee M, et al. Barriers and facilitators to optimal oral anticoagulant management: a scoping review. J Thromb Thrombolysis. 2020;50(3):697\u2013714.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"337_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257798","volume":"16","author":"A Holbrook","year":"2021","unstructured":"Holbrook A, Wang M, Swinton M, et al. Barriers and facilitators for optimizing oral anticoagulant management: perspectives of patients, caregivers, and providers. PLoS ONE. 2021;16(9):e0257798.","journal-title":"PLoS ONE"},{"issue":"4","key":"337_CR43","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(24)00027-4","volume":"12","author":"HA Ghofrani","year":"2024","unstructured":"Ghofrani HA, Simonneau G, D\u2019Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2024;12(4):e21\u201330.","journal-title":"Lancet Respir Med"},{"key":"337_CR44","unstructured":"A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive phase 3 study with open-label extension to evaluate efficacy and safety of Macitentan 75 mg in inoperable or persistent\/recurrent chronic thromboembolic pulmonary hypertension [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04271475."},{"key":"337_CR45","unstructured":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent\/recurrent after surgical and\/or interventional treatment chronic thromboembolic pulmonary hypertension [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03689244."},{"issue":"10","key":"337_CR46","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.sapharm.2021.01.012","volume":"17","author":"SM Price","year":"2021","unstructured":"Price SM, O\u2019Donoghue AC, Rizzo L, Sapru S, Aikin KJ. What influences healthcare providers\u2019 prescribing decisions? Results from a national survey. Res Social Adm Pharm. 2021;17(10):1770\u20139.","journal-title":"Res Social Adm Pharm"},{"issue":"1","key":"337_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000263","volume":"5","author":"J Yorke","year":"2018","unstructured":"Yorke J, Deaton C, Campbell M, et al. Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respir Res. 2018;5(1):e000263.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"337_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12380","volume":"14","author":"GEM Reeves","year":"2024","unstructured":"Reeves GEM, Shepherd J, Collins NJ, Twaddell S, Harjit Singh R. Assessing quality of life in pulmonary arterial hypertension: an independent prognostic marker. Pulm Circ. 2024;14(2):e12380.","journal-title":"Pulm Circ"},{"issue":"3","key":"337_CR49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. Us population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"key":"337_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051388","author":"L Pleyer","year":"2023","unstructured":"Pleyer L, Heibl S, Tinchon C, et al. Health-related quality of life as assessed by the EQ-5D-5L predicts outcomes of patients treated with azacitidine\u2014A prospective cohort study by the AGMT. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051388.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"337_CR51","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00337-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:31:19Z","timestamp":1773667879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00337-8","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Belinda Rivera-Lebron and Alison Witkin received consulting fees from Johnson and Johnson Innovative Medicine. Carly J Paoli, Sumeet Panjabi, and Gabriela Gomez Rendon are (or were at the time the study was conducted) employees of Actelion Pharmaceuticals US, Inc, a Johnson and Johnson company. Mark Small, Mia Harvey and Daniel Graham are full-time employees of Adelphi Real World, an agency which received a subscription fee for data access and analysis. Josanna Rodriguez-Lopez received consulting fees from Johnson and Johnson Innovative Medicine, Merck group, Bayer AG, and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The DSP was conducted in line with European Pharmaceutical Market Research Association guidelines [\n                      \n                      ], as well as all other relevant guidelines, including: the Health Insurance Portability and Accountability Act [\n                      \n                      ], Health Information Technology for Economic and Clinical Health Act [\n                      \n                      ], and the Declaration of Helsinki of 1964 and its later amendments [\n                      \n                      ]. In addition, ethical exemption was provided by the Pearl institutional review board (protocol number: 2023-0280). No personally identifiable information was collected, and all data were pseudonymized by assigning responses a code that allowed for matching between physician and patient responses. Patients provided informed consent in the PSC for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected such that patients and clinicians could not be identified directly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}